Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Nicholas K. Hurlburt; Emilie Seydoux; Yu-Hsin Wan; Venkata Viswanadh Edara; Andrew B. Stuart; Junli Feng; Mehul S. Suthar; Andrew T. McGuire; Leonidas Stamatatos; Marie Pancera

doi:10.1038/s41467-020-19231-9

Nature Communications (Oct 2020)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Nicholas K. Hurlburt,
Emilie Seydoux,
Yu-Hsin Wan,
Venkata Viswanadh Edara,
Andrew B. Stuart,
Junli Feng,
Mehul S. Suthar,
Andrew T. McGuire,
Leonidas Stamatatos,
Marie Pancera

Affiliations

Nicholas K. Hurlburt: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Emilie Seydoux: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Yu-Hsin Wan: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Venkata Viswanadh Edara: Division of Infectious Disease, Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine
Andrew B. Stuart: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Junli Feng: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Mehul S. Suthar: Division of Infectious Disease, Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine
Andrew T. McGuire: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Leonidas Stamatatos: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division
Marie Pancera: Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division

DOI: https://doi.org/10.1038/s41467-020-19231-9
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 7

Abstract

Read online

Currently there is neither a vaccine nor an effective treatment strategy available for COVID19. Here, Hurlburt et al. provide the crystal structure of a patient-derived monoclonal antibody neutralizing SARS-CoV-2 via shedding of the S1 subunit and competing for the receptor binding domain.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal